secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0000950170-24-068304
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari closes ~$7.6M private placement of ADSs and warrants
----------------------------------------------------------

- Sold 3,817,553 ADSs and warrants at $1.885/unit to investors including chairman and interim CEO; 212,201 units to close later.
- Warrants exercisable for 3 years at $1.76/ADS; insider warrants at $1.79/ADS.
- Paid Paulson Investment Co. 8% cash fee and issued placement agent warrants for 332,380 ADSs at $1.885, 5-year term.
- Company to file resale registration statement with SEC by June 28, 2024.
- Securities issued under Section 4(a)(2) and Regulation D; accredited investors only.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024068304/0000950170-24-068304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024068304/aktx-20240529.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-068304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer